Resource-sparing and cost-effective strategies in current management of breast cancer

Journal of Cancer Research and Therapeutics

Volumn 5, Issue 2, 2009, Pages 116-120

  Munshi, Anusheel ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Breast cancer; Cost effective; Resource sparing

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DOCETAXEL; DRUG METABOLITE; ENDOXIFEN; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; LAPATINIB; METHOTREXATE; NAVELBINE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG COST; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; RADIATION DOSE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; RESOURCE ALLOCATION;

EID: 67749108603     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.52797     Document Type: Article

References (46)

1. Tongbai R, Idelman G, Nordgard SH, Cui W, Jacobs JL, Haggerty CM, et al. Transcriptional networks inferred from molecular signatures of breast cancer. Am J Pathol 2008;10:212-5.
2. Algara López M, Sanz Latiesas X, Foro Arnalot P, Lacruz Bassols M, Reig Castillejo A, Lozano Galán J, et al. Use of radiation treatment units in breast cancer: Changes in the last 15 years. Clin Transl Oncol 2008;10:47-51.
3. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: A descriptive review. Nat Clin Pract Oncol 2007;4:643-56.
4. Martens E. The prevention and treatment (and cost) of cancer. ACS Chem Biol 2007;19;637-9.
5. Lucci A, Shoher A, Sherman MO, Azzizadeh A. Assessment of the current Medicare reimbursement system for breast cancer operations. Ann Surg Oncol 2004;11:1037-44.
6. Moore KA. Breast cancer patients' out-of-pocket expenses. Cancer Nurs 1999;22:389-96.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1687-717.
8. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002;359:2131-9.
9. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Intergroup Exemestane Study: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007;369:559-70
10. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J Clin Oncol 2007;25:2664-70.
11. Punglia RS, Winer EP, Weeks JC, Burstein HJ. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. J Clin Oncol 2007;25:502.
12. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412-3.
13. Munshi A, Singh P. Tamoxifen in breast cancer: Not so easy to write off. Breast 2008;17:121-4.
14. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-34.
15. Travis K. Anastrozole data show continued delay in relapse but no clear survival advantage. J Natl Cancer Inst 2005;97:2.
16. Cocquyt V, Moeremans K, Annemans L, Clarys P, Van Belle S. Long-term medical costs of postmenopausal breast cancer therapy. Ann Onc 2003;14:1057-63.
17. Curr Index Med Specialties 2002;77:507.
18. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
19. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic
20. breast cancer: A phase III, multinational, randomized controlled trial. N Engl J Med 2001;344:783-92.
21. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
22. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11:4-12.
23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
24. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
25. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
26. GlaxoSmithKline: TYKERB label. Available from: http://us.gskr.com/ products/assets/us-tykerb.pdf.
27. Reddy N, Cohen R, Whitehead B. A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmacol Ther 2007;81:S16-7.
28. Ratain MJ, Cohen EE. The value meal: How to save $1,700 per month or more on lapatinib. J Clin Oncol 2007;25:3397-8.
29. Paik S, Taniyama Y, Geyer CE Jr. Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst 2008;100:2-4.
30. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993;341:1293-8.
31. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The zoladex early breast cancer research association study. J Clin Oncol 2002;20:4628-35.
32. International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95:1833-46.
33. Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006;24:4956-62.
34. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data.
35. Radiother Oncol 1990;19:219-35.
36. Dinshaw KA, Sarin R, Budrukkar AN, Shrivastava SK, Deshpande DD, Chinoy RF, et al. Safety and feasibility of breast conserving therapy in Indian women: Two decades of experience at Tata Memorial Hospital. J Surg Oncol 2006;94:105-13.
37. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143-50.
38. Shelley W, Brundage M, Hayter C, Paszat L, Zhou S, Mackillop W. A shorter fractionation schedule for post lumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys 2000;47:1219-28.
39. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: Long-term results of a randomised trial. Radiother Oncol 2005;75:9-17.
40. Munshi A, Budrukkar A. Hypofractionated radiation therapy in breast cancer: A revolutionary breakthrough or a long way to go? J Clin Oncol 2007;25:458-9.
41. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 2000;355:1757-70.
42. Munshi A. Breast cancer radiotherapy and cardiac risk: The 15-year paradox. J Cancer Res Ther 2007;3:190-2.
43. Jalali R, Singh S, Budrukkar A. Techniques of tumour bed boost irradiation in breast conserving therapy: Current evidence and suggested guidelines. Acta Oncol 2007;46:879-92.
44. Chadha M, Woode R, Sillanpaa J, Feldman S, Boolbol S, Furhang E, et al. Three-week Accelerated Radiation Therapy (ART) schedule with a concomitant in-field boost as treatment for early stage breast cancer. Int J Radiat Oncol Biol Phys 2007;69:S137.
45. rd, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798-804.
46. Salazar OM, Sandhu T, da Motta NW, Escutia MA, Lanzós-Gonzales E, Mouelle-Sone A, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: A randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001;50:765-75.